Latest Nx Capital Co. (NXCP) Headlines NX Capital Co.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Nx Capital Co. (NXCP) Headlines

NX Capital Co. Announces Obtaining OTC Pink Current Status
Marketwire - Tue Feb 25, 9:15AM CST
NX Capital Co. (OTC Pink: NXCP) announced today that the Company has achieved OTC Pink Current reporting status as of this morning. The company filed the requested financial information and the OTC changed the reporting status today.

NX Capital Co. Announces Management Change
Marketwire - Thu Feb 13, 9:15AM CST
NX Capital Co. (OTC Pink: NXCP) announced today that John Conroy has been appointed as the Company's Chief Executive Officer and as a Director and Chairman of the Board. Mr. Conroy is an experienced executive and entrepreneur with more than 30 years of financial and CEO experience. His expertise focuses on turn around and start-up operations of new and existing companies. In his new role, Mr. Conroy will focus on building an exploration company positioned in the Uranium industry in the United States.

NX Capital Co. Recruits Experienced Management Team
Marketwire - Wed Nov 20, 1:00PM CST
NX Capital Co. (OTC Pink: NXCP) announced today that F. Jeffrey Krupka has resigned from the Board of Directors and all other positions with the Company. Mr. Krupka has been instrumental in reshaping NX Capital's business model to become a uranium holding and exploration company.

NX Capital Co. Retracts September 12, 2013 and September 18, 2013 Press Releases
ACCESSWIRE - Thu Sep 19, 8:20AM CDT
DENVER, CO, September 19, 2013 - (ACCESSWIRE) - NX CAPITAL, CO (OTC Pink: NXCP), after review of recent press releases made on September 12, 2013 and September 18, 2013 has retracted such press releases due to erroneous information disclosed regarding NX Capital's recent corporate activities.

NX Capital Announces FINRA's Acceptance of Reorganization, Name Change and New Symbol (NXCP.pk)
ACCESSWIRE - Wed Sep 18, 10:11AM CDT
NEXHorizon Name and Symbol Change Cleared - Now NX Capital Co. (NXCP.pk)

DRJ International Group Ltd Inc. (DRJG) Stock Research Links

DRJG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading